Evidence map›Paper›PMID 28082743›Full record

ArticleExperimental & molecular medicine2017

Adipose stem cell-derived nanovesicles inhibit emphysema primarily via an FGF2-dependent pathway.

You-Sun Kim, Ji-Young Kim, RyeonJin Cho, Dong-Myung Shin, Sei Won Lee, Yeon-Mok Oh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental & molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Extracellular vesicles and COPD: foe or friend?Journal of nanobiotechnology · 2023
    Review
  18. Review
  19. Biofabrication of nanovesicles for brain diseases.Neural regeneration research · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

You-Sun KimAsan Institute for Life Sciences, Seoul, Korea.
Ji-Young KimAsan Institute for Life Sciences, Seoul, Korea.
RyeonJin ChoDepartment of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Dong-Myung ShinDepartment of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, Korea.ORCID 0000-0002-0511-5750
Sei Won LeeDepartment of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Yeon-Mok OhDepartment of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Ulsan College · KRAsan Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapy using stem cells has produced therapeutic benefits in animal models of COPD. Secretory mediators are proposed as one mechanism for stem cell effects because very few stem cells engraft after injection into recipient animals. Recently, nanovesicles that overcome the disadvantages of natural exosomes have been generated artificially from cells. We generated artificial nanovesicles from adipose-derived stem cells (ASCs) using sequential penetration through polycarbonate membranes. ASC-derived artificial nanovesicles displayed a 100 nm-sized spherical shape similar to ASC-derived natural exosomes and expressed both exosomal and stem cell markers. The proliferation rate of lung epithelial cells was increased in cells treated with ASC-derived artificial nanovesicles compared with cells treated with ASC-derived natural exosomes. The lower dose of ASC-derived artificial nanovesicles had similar regenerative capacity compared with a higher dose of ASCs and ASC-derived natural exosomes. In addition, FGF2 levels in the lungs of mice treated with ASC-derived artificial nanovesicles were increased. The uptake of ASC-derived artificial nanovesicles was inhibited by heparin, which is a competitive inhibitor of heparan sulfate proteoglycan that is associated with FGF2 signaling. Taken together, the data indicate that lower doses of ASC-derived artificial nanovesicles may have beneficial effects similar to higher doses of ASCs or ASC-derived natural exosomes in an animal model with emphysema, suggesting that artificial nanovesicles may have economic advantages that warrant future clinical studies.

Indexed as

Signal TransductionAdipose TissueAnimalsBiomarkersCell-Derived MicroparticlesCell LineEmphysemaEndocytosisExosomesFibroblast Growth Factor 2MicePhenotypeStem CellsBiomarkersFibroblast Growth Factor 2

Identifiers

PMID28082743
PMCPMC5291836
OpenAlexW2576914658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.